The relaxant effect of nicardipine on the isolated uterine smooth muscle of the pregnant rat

Dong Joon Kim1,2, Mi Ha Hwang1, Tae Hun An1,2, and Ki Tae Jung1,2

Department of Anesthesiology and Pain Medicine, 1Chosun University Hospital, 2Chosun University School of Medicine, Gwangju, Korea

Background: Nicardipine, a calcium channel blocker, is used to treat hypertension in pregnancy or preterm labor. The current study was conducted to investigate the relaxant effects of nicardipine on the isolated uterine smooth muscle of the pregnant rat.

Methods: We obtained uterine smooth muscle strips from pregnant female SD rats. After uterine contraction with oxytocin 10 mU/ml, we added nicardipine (10⁻¹² to 10⁻⁸ M) accumulatively every 20 min. We recorded active tension and frequency of contraction, and calculated EC₅₀ (effective concentration of 5% reduction), EC₂₅, EC₅₀, EC₇₅, and EC₉₅ of active tension and frequency of contraction using a probit model.

Results: Nicardipine (10⁻¹² to 10⁻⁸ M) decreased active tension and frequency of contraction in a concentration-dependent manner. The EC₅₀ and EC₉₅ of nicardipine in the inhibition of active tension of the uterine smooth muscle were 2.41 × 10⁻¹⁰ M and 3.06 × 10⁻⁷ M, respectively. The EC₅₀ and EC₉₅ of nicardipine in the inhibition of frequency of contraction of the uterine smooth muscle were 9.04 × 10⁻¹¹ and 4.18 × 10⁻⁷ M, respectively.

Conclusions: Nicardipine relaxed and decreased the frequency of contraction of the uterine smooth muscle in a concentration-dependent pattern. It might be possible to adjust the clinical dosage of nicardipine in the obstetric field based on our results, but further clinical studies are needed to confirm them.

Keywords: Nicardipine; Rat; Relaxation; Smooth muscle; Uterine contraction; Uterus.

INTRODUCTION

Nicardipine is a calcium channel blocker (CCB) frequently used for hypertension [1]. In the obstetric field, nicardipine is used not only to treat severe hypertension in pregnancy [2] but also to manage threatened preterm labor [3]. Spontaneous contraction of the uterus is regulated by intrauterine calcium concentration, and intracellular free Ca²⁺ acts as a primary regulator [4]. Therefore, it is obvious that nicardipine decreases uterine contractility because it acts as an antagonist of calcium influx through the slow channel of the cell membrane [1]. However, there are few reports about the effective plasma concentration of nicardipine to prevent preterm labor or to treat pregnancy-induced hypertension (PIH), and the relationship between plasma concentration of nicardipine and uterine contractility.

We conducted this study to investigate the relaxant effects of nicardipine on the isolated uterine smooth muscle of the pregnant rat. Furthermore, we aimed to compare the effective concentration for the clinical use of nicardipine in obstetric anesthesia and calculate the effective concentration.

MATERIALS AND METHODS

The current study was conducted after approval of the Animal Care and Use Committee (no. CIACUC2018-S0043) and...
followed the ARRIVE guidelines [5]. Female Sprague–Dawley rats (18th day of pregnancy, weighing 200–250 g) were used for the study (n = 10). The rat was killed by inhalation of carbon dioxide, and the abdomen was opened immediately through a midline incision. The pregnant uterus was isolated and dissected in a petri dish filled with Krebs solution; which was composed of 118.3 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl₂, 25 mM NaHCO₃, 1.2 mM KH₂PO₄, 1.2 mM MgCl₂, and 11.1 mM glucose [6]. After removing connective tissues, uterine smooth muscle tissue was dissected into strips of the myometrium (approximately 5 × 10 mm). The uterine smooth muscle strip was mounted in the tissue baths (25 ml of volume) filled with Krebs solution; maintained at 37°C by circulating the heated water in the space between the double walls, and continuously aerated with a gas mixture of 95% oxygen and 5% carbon dioxide; approximate pH was 7.4. One end of the muscle strip was connected to a hook placed on the base of the bath, and the other end of the muscle strip was connected to a hook which was extended from the lever arm of a force-displacement transducer (Isometric transducer, 50–7905, Havard App Ltd., USA).

The isometric tension of the myometrial strips was measured using the force displacement transducer and the recorded the traces with an i-WORX 118 system (USA) interfaced via Labscribe software (Windows ver. 2.0, i-Worx Systems Inc.). After applying an initial resting tension of 2.0 g, the uterine smooth muscle strips were equilibrated for 60 min in the bath by flushing fresh solution every 20 min. After the development of rhythmic spontaneous contractions, oxytocin 10 mU/ml was added to the bath and the strips were allowed to equilibrate for a further 60 min. After strong contraction had been accomplished, the parameters of the contraction during the 20 min before application of nicardipine were used as controls. Then, nicardipine (Perdipine, Donga, Korea) in various concentrations (10⁻¹² to 10⁻⁸ M) was added to the bath accumulatively every 20 min, and the change of the contraction pattern was observed. Quantitative changes of uterine contractility were expressed by assessing two parameters: active tension (an increase of tension between peak tension and resting tension during muscle contraction), and frequency of contraction (the number of contractions during 20 min for the application of each concentration of nicardipine).

All obtained results are expressed as mean ± standard deviation. The inhibitory effects of nicardipine according to the concentration was assessed by comparing the control and measured data, which were described as a percentage. The statistical significance was analyzed by the Kruskal–Wallis test and Mann–Whitney U test with Bonferroni’s correction using SPSS (Windows ver. 21.0, SPSS Inc., USA). P values less than 0.05 were considered statistically significant. Effective concentration (EC) of nicardipine needed to inhibit active tension or frequency of contractions of the myometrium was calculated using a probit analysis [7], and described as it as EC₅ (effective concentration of 5% reduction), EC₂₅, EC₅₀, EC₇₅, and EC₉₅ (95% confidence interval, CI).

RESULTS

Nicardipine (10⁻¹² to 10⁻⁸ M) decreased active tension and frequency of contraction in a concentration-dependent manner (Table 1). A significant decrease of active tension and frequency of contraction were shown from the concentration of 10⁻¹¹ M (P < 0.05). The EC₉₅ and EC₅₀ of nicardipine in the inhibition of active tension of the uterine smooth muscle were 2.41 × 10⁻¹⁰ M (95% CI [3.33 × 10⁻¹¹ M, 3.15 × 10⁻⁹ M]) and 3.06 × 10⁻⁷ M (95% CI [1.23 × 10⁻⁸ M, 4.16 × 10⁻⁷ M]), respectively (Table 2, Fig. 1). The EC₉₅ and EC₅₀ of nicardipine in the

| Concentration (M) | Active tension (g) | Inhibition (%) of active tension | P value | Frequency of contraction (n) | Inhibition (%) of frequency of contraction | P value |
|-------------------|--------------------|---------------------------------|---------|-----------------------------|------------------------------------------|---------|
| Control           | 3.53 ± 0.26        | -                               | -       | 29.5 ± 2.51                 | -                                        | -       |
| 10⁻¹²             | 3.39 ± 0.15        | 13.62 ± 7.92                    | < 0.120 | 26.5 ± 3.06                 | 3.76 ± 4.94                              | 0.005   |
| 10⁻¹¹             | 2.29 ± 0.13        | 43.48 ± 8.58                    | < 0.001 | 14.3 ± 1.94                 | 35.00 ± 4.98                             | < 0.001 |
| 10⁻¹⁰             | 2.10 ± 0.08        | 48.55 ± 10.90                   | < 0.001 | 12.6 ± 1.43                 | 40.18 ± 5.31                             | < 0.001 |
| 10⁻⁹              | 1.39 ± 0.24        | 65.34 ± 9.83                    | < 0.001 | 10.0 ± 1.94                 | 60.35 ± 7.93                             | < 0.001 |
| 10⁻⁸              | 0.70 ± 0.19        | 82.60 ± 4.15                    | < 0.001 | 6.70 ± 1.16                 | 80.09 ± 5.35                             | < 0.001 |

Data are expressed as mean ± SD.
inhibition of frequency of contraction of the uterine smooth muscle were 9.04 × 10^{-11} M (95% CI [1.57 × 10^{-11} M, 4.91 × 10^{-10} M]) and 4.18 × 10^{-7} M (95% CI [2.05 × 10^{-8} M, 1.66 × 10^{-7} M]), respectively (Table 2, Fig. 2).

**DISCUSSION**

Uterine contractility is generated by contractions of myometrial smooth muscle cells [8]. Contraction of the myometrial smooth muscle is initiated by depolarization of the cell membrane triggered by the entry of Ca\textsuperscript{2+} into the cells. An influx of Ca\textsuperscript{2+} into the cells contribute to a rise in the intracellular Ca\textsuperscript{2+} concentration, and an increase in Ca\textsuperscript{2+} concentration leads to a chain reaction of contractions of uterine smooth muscles. Oxytocin stimulates uterine contractions by activating the oxytocin receptor, which triggers elevation of the intracellular Ca\textsuperscript{2+} concentration [9]. Therefore, the concentration of Ca\textsuperscript{2+} plays a key role in the contraction of the uterus.

Nicardipine is a CCB that inhibit the influx of Ca\textsuperscript{2+} into the cells [1]. Usually, it is used to treat hypertension, congestive heart failure, and cerebrovascular disease. However, it is also used in the obstetric field for PIH [2] or preterm labor [3]. Because nicardipine reduces intracellular Ca\textsuperscript{2+}, use of nicardipine in pregnancy can decrease uterine contractility. Nicardipine is an effective drug for the treatment of PIH or preeclampsia [2,10], and the relaxation effect on the uterus is useful in treating preterm labor [3]. However, the effect of nicardipine on uterine contractions according to the concentration is still questionable. There are few reports about effective plasma concentration in inhibiting the contraction of the uterus in preterm labor, and besides nicardipine to treat PIH may be associated with uterine atony after delivery by Cesarean section. Thus, we wanted to compare the plasma concentration in the clinical use of nicardipine and estimated

---

**Table 2. Effective Concentrations (M) of Nicardipine for the Inhibition of Active Tension and Frequency of Contraction in the Uterine Smooth Muscle of Pregnant Rats (n = 10)**

| Concentration (M) | EC\textsubscript{50} | EC\textsubscript{25} | EC\textsubscript{50} | EC\textsubscript{75} | EC\textsubscript{95} |
|------------------|-----------------|-----------------|-----------------|-----------------|------------------|
| Active tension (g) | 1.90 × 10^{-13} | 1.29 × 10^{-13} | 2.41 × 10^{-10} | 4.52 × 10^{-9} | 3.06 × 10^{-7} |
| Frequency of contraction (n) | 1.95 × 10^{-14} | 2.84 × 10^{-12} | 9.04 × 10^{-12} | 2.88 × 10^{-9} | 4.18 × 10^{-7} |

Data are expressed estimated value (95% confidence interval). EC: effective concentration.
plasma concentration by means of an in vitro study.

In human study of nicardipine treatment of PIH, maternal plasma concentration of nicardipine was 54.6 ng/ml after intravenous infusion (2–6 mg/h) [10], which is $1.14 \times 10^{-3}$ M. This plasma concentration is about $2.28 \times 10^{-3}$ M in vitro, because 98% of nicardipine given intravenously is bound to plasma protein [11]. Maternal nicardipine concentrations of the pregnant with severe pre-eclampsia who were treated with intravenous infusions of nicardipine (3–10 mg/h) ranged from 9.8 to 116 ng/ml, which is $2.04 \times 10^{-5}$ M to $2.42 \times 10^{-3}$ M [11]. This plasma concentration is about $4.08 \times 10^{-6}$ M in vitro. The EC$_{95}$ of nicardipine that inhibits the active tension and frequency of contraction of the uterine smooth muscle in the current study was $3.06 \times 10^{-7}$ M (95% CI [1.23 \times 10^{-8}$ M, $4.16 \times 10^{-7}$ M]) and $4.18 \times 10^{-7}$ M (95% CI [2.05 \times 10^{-8}$ M, $1.66 \times 10^{-7}$ M]), respectively. Thus, nicardipine, which is commonly used clinically for the treatment of PIH or pre-eclampsia, would decrease uterine contraction. In fact, the plasma concentration of nicardipine decreases rapidly after an intravenous infusion because of its initial rapid distribution half-life (2.7 min) [12]. As far as we know, there is still no report of uterine atony associated with nicardipine use for PIH or pre-eclampsia. The concentration of nicardipine seems to fall fast because of its short half-life, and the use of nicardipine in the pregnant with hypertension would be safe in terms of uterus contraction after delivery. However, it seems possible to reduce the dosage of nicardipine in the treatment of PIH according to the results of this study.

On the other hand, the use of nicardipine to prevent preterm labor needs a sufficient concentration of plasma nicardipine to relax the uterus. As far as we know, there is still no report about the maternal plasma concentration of nicardipine. However, peak maternal nicardipine concentrations ranged from 175 to 865 ng/ml according to the animal study using rhesus macaques [13]. This plasma concentration is about $3.65 \times 10^{-3}$ M to $1.80 \times 10^{-2}$ M, which are $7.30 \times 10^{-3}$ M to $3.61 \times 10^{-4}$ M in vitro. These concentrations are larger than the EC$_{95}$ for relaxing and decreasing the frequency of contraction of the uterine smooth muscle in this study which were $3.06 \times 10^{-7}$ M and $4.18 \times 10^{-7}$ M, respectively. Another in vitro study about the inhibition of uterine contractility by nicardipine showed EC$_{95}$ and EC$_{95}$ for the inhibition were $5.8 \times 10^{-9}$ M and $2.6 \times 10^{-8}$ M, respectively [14]. EC$_{95}$ and EC$_{95}$ for the inhibition of uterine contraction of this study were $2.41 \times 10^{-10}$ M and $4.51 \times 10^{-9}$ M, respectively. The uterine relaxations were achieved at the lower concentrations in our study. It seems that the discrepancies between our results and those of previous animal studies resulted from the differences in methodology (solutions, measurement apparatus, time interval, basal tension, calculating method for estimated EC, etc.). However, the plasma concentrations of nicardipine which are used for preterm labor seem to be sufficient to decrease contractility and the frequency of contraction of the uterine smooth muscle.

According to the results of our study, it seems that it may be possible to decrease the dosage of nicardipine in the treatment of PIH or preterm labor. The concentrations of nicardipine in the PIH treatment of previous clinical studies [10,11] or in the treatment of preterm labor in animal studies [13,14] are much higher than the calculated concentrations of our study. Nicardipine treatment as a tocolytic has side effects, such as hypotension or maternal pulmonary edema [3]. Especially, pulmonary edema after use of nicardipine is mainly associated with preterm labor, and it is a severe complication for which the patients needed hospitalization in an intensive care unit [15]. Thus, limiting the dosage to what is needed to achieve the effective concentration for uterine relaxation and to avoid maternal complications is important. However, validations are needed to extrapolate the results of this study for the clinical use because of possible species differences and in vivo/vitro differences, and this is the limitation of our study. Another well-designed clinical study is needed to find out the minimal effective concentration of nicardipine in the treatment of preterm labor.

In conclusion, nicardipine (from $10^{-12}$ to $10^{-8}$ M) relaxed and decreased the frequency of contraction of the uterine smooth muscle as a concentration-dependent pattern. The EC$_{95}$ for decreasing the active tension and the frequency of contraction were $3.06 \times 10^{-7}$ M and $4.18 \times 10^{-7}$ M, respectively. It may be possible to adjust the clinical dosage of nicardipine in the obstetric field based on the results of this study. Further clinical studies are needed to confirm our results.

**ACKNOWLEDGMENTS**

This research was supported by Research Grant funded by a Korean Society of Obstetric Anesthesiologists, 2017.
CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ORCID

Dong Joon Kim: https://orcid.org/0000-0002-3072-4734
Mi Ha Hwang: https://orcid.org/0000-0002-7881-3015
Tae Hun An: https://orcid.org/0000-0002-7405-0073

REFERENCES

1. Sorkin EM, Clissold SP. Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs 1987; 33: 296-345.
2. Nij Bijvank SW, Duvekot JJ. Nicardipine for the treatment of severe hypertension in pregnancy: a review of the literature. Obstet Gynecol Surv 2010; 65: 341-7.
3. Gáspár R, Hajagos-Tóth J. Calcium channel blockers as tocolytics: principles of their actions, adverse effects and therapeutic combinations. Pharmaceuticals (Basel) 2013; 6: 689-99.
4. Wray S. Uterine contraction and physiological mechanisms of modulation. Am J Physiol 1993; 264(1 Pt 1): C1-18.
5. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG; National Centre for the Replacement, Refinement and Reduction of Animals in Research. Animal research: reporting in vivo experiments—the ARRIVE guidelines. J Cereb Blood Flow Metab 2011; 31: 991-3.
6. Chung CD, An TH, Jung KT, Lee TH. The effects of etomidate on the contraction of pregnant rat uterine smooth muscle. Korean J Anesthesiol 2009; 57: 84-7.
7. Lee SI, Hwang GB, Baik CY. The relationship of the estimates of effective concentration calculated by logit, probit, and sigmoid emax. Korean J Anesthesiol 2002; 43: 345-7.
8. Bursztyn L, Eytan O, Jaffa AJ, Elad D. Mathematical model of excitation-contraction in a uterine smooth muscle cell. Am J Physiol Cell Physiol 2007; 292: C1816-29.
9. Arrowsmith S, Wray S. Oxytocin: its mechanism of action and receptor signalling in the myometrium. J Neuroendocrinol 2014; 26: 356-69.
10. Carbonne B, Jannet D, Touboul C, Khelifati Y, Milliez J. Nicardipine treatment of hypertension during pregnancy. Obstet Gynecol 1993; 81: 908-14.
11. Bartels PA, Hanff LM, Mathot RA, Steegers EA, Vulto AG, Visser W. Nicardipine in pre-eclamptic patients: placental transfer and disposition in breast milk. BJOG 2007; 114: 230-3.
12. Curran MP, Robinson DM, Keating GM. Intravenous nicardipine: its use in the short-term treatment of hypertension and various other indications. Drugs 2006; 66: 1755-82.
13. Ducsay CA, Thompson JS, Wu AT, Novy MJ. Effects of calcium entry blocker (nicardipine) tocolysis in rhesus macaques: fetal plasma concentrations and cardiorespiratory changes. Am J Obstet Gynecol 1987; 157: 1482-6.
14. Doret M, Mellier G, Gaucherand P, Saade GR, Benchaib M, Frutoso J, et al. The in vitro effect of dual combinations of ritodrine, nicardipine and atosiban on contractility of pregnant rat myometrium. BJOG 2003; 110: 731-4.
15. Serena C, Begot E, Cros J, Hodler C, Fedou AL, Nathan-Denizot N, et al. Nicardipine-induced acute pulmonary edema: a rare but severe complication of tocolysis. Case Rep Crit Care 2014; 2014: 242703.